Scarica l'app Stockscreener
0.3752
1.19%
-0.0045
Dopo l'orario di chiusura:
.38
0.0048
+1.28%
Precedente Chiudi:
$0.3797
Aprire:
$0.3753
Volume 24 ore:
736.51K
Relative Volume:
0.56
Capitalizzazione di mercato:
$22.22M
Reddito:
-
Utile/perdita netta:
$-41.95M
Rapporto P/E:
-0.452
EPS:
-0.83
Flusso di cassa netto:
$-38.34M
1 W Prestazione:
-0.90%
1M Prestazione:
-1.68%
6M Prestazione:
-47.25%
1 anno Prestazione:
-87.02%
Intervallo 1D:
$0.3701
$0.3755
Intervallo di 1 settimana:
$0.3633
$0.388
Portata 52W:
$0.221
$3.09
Elevation Oncology Inc Stock (ELEV) Company Profile
Nome
Elevation Oncology Inc
Settore
Industria
Telefono
(716) 371-1125
Indirizzo
101 FEDERAL STREET, BOSTON
Confronta ELEV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.3752 | 22.43M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2025-03-21 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-03-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-05-30 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2021-12-23 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Elevation Oncology Inc Borsa (ELEV) Ultime notizie
what makes elevation oncology inc. stock price move sharplySmart Trading With Safety Margin - Newser
Why Elevation Oncology Inc. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - Newser
How Elevation Oncology Inc. stock performs during market volatilityMulti Bagger Alerts - Newser
What makes Elevation Oncology Inc. stock price move sharplyChart Based Entries - Newser
Elevation Oncology Terminates EO-3021 Study Amid Implications for Future Research and Development Strategies - AInvest
EO-3021 Study Termination: Implications for Elevation Oncology and Partners - TipRanks
Elevation Oncology Terminates License Agreement with CSPC - TipRanks
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $3.39 Average PT from Brokerages - Defense World
Analyzing Ratios: Elevation Oncology Inc (ELEV)’s Financial Story Unveiled - DWinneX
Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Decline in Short Interest - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
Research Analysts Set Expectations for ELEV FY2025 Earnings - Defense World
Q2 Earnings Estimate for ELEV Issued By Leerink Partnrs - Defense World
Equities Analysts Issue Forecasts for ELEV Q3 Earnings - Defense World
Wedbush Forecasts Reduced Earnings for Elevation Oncology - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at TD Cowen - Defense World
HC Wainwright Downgrades Elevation Oncology (NASDAQ:ELEV) to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by HC Wainwright - Defense World
Elevation Oncology (NASDAQ:ELEV) Downgraded by HC Wainwright to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Receives Market Perform Rating from JMP Securities - Defense World
Elevation Oncology (NASDAQ:ELEV) Lowered to Hold Rating by William Blair - Defense World
Elevation Oncology’s (ELEV) Neutral Rating Reaffirmed at HC Wainwright - Defense World
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc.ELEV - Business Wire
Elevation Oncology (ELEV) Receives Analyst Rating Update | ELEV Stock News - GuruFocus
This McDonald's Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Elevation Oncology (ELEV) Receives Downgrade from HC Wainwright & Co. | ELEV Stock News - GuruFocus
TD Cowen Downgrades Elevation Oncology to Hold From Buy - MarketScreener
HC Wainwright Downgrades Elevation Oncology to Neutral From Buy - marketscreener.com
Elevation Oncology (ELEV) Downgraded by H.C. Wainwright Amid Mer - GuruFocus
Elevation Oncology agrees to be acquired by Concentra - The Pharma Letter
Jane Street Group LLC Acquires 41,215 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Millennium Management LLC Boosts Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology agrees to Concentra Biosciences buyout By Investing.com - Investing.com South Africa
Elevation Oncology (ELEV) Downgraded Following Acquisition News - GuruFocus
Elevation Oncology (ELEV) Downgraded by William Blair Following Acquisition Announcement | ELEV Stock News - GuruFocus
Elevation Oncology (ELEV) to be Acquired by Concentra Biosciences | ELEV Stock News - GuruFocus
Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’ - BioPharma Dive
Elevation Oncology Accepts a Buyout Offer from Concentra Biosciences - marketscreener.com
Concentra Biosciences, LLC entered into a definitive merger agreement to acquire Elevation Oncology, Inc. for $21.4 million. - marketscreener.com
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders - Business Wire
Elevation Oncology stock soars on Concentra merger agreement By Investing.com - Investing.com Nigeria
Elevation Oncology stock soars on Concentra merger agreement - Investing.com Australia
Concentra buys out another struggling Boston biotech - The Business Journals
Elevation Oncology Inc Azioni (ELEV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):